Insilico's AI-discovered lung fibrosis drug enters Phase III

Insilico Medicine's AI-discovered lung fibrosis drug, Rentosertib, has entered Phase III clinical trials for idiopathic pulmonary fibrosis, marking a rare late-stage test for AI drug discovery. The company claims it is the first end-to-end AI-discovered drug candidate to reach this stage, with Phase IIa results published in Nature Medicine supporting the advancement.

Insilico Medicine says its lead drug candidate, Rentosertib https://insilico.com/pipeline/tnik sc?ref=runtimewire , has entered a Phase III clinical trial for idiopathic pulmonary fibrosis IPF , giving AI drug discovery a rare late-stage test. In its announcement https://insilico.com/news/xmjsn4l091-insilico-initiates-phase-iii-clinical-tr?amp=true&ref=runtimewire , the company characterizes Rentosertib as the first "end-to-end AI-discovered" drug candidate to reach Phase III; that remains Insilico's claim and depends on how "end-to-end" is defined. Rentosertib is an oral small-molecule inhibitor of TNIK TRAF2- and NCK-interacting kinase . Insilico points to results from a randomized phase 2a trial in IPF published in Nature Medicine https://www.nature.com/articles/s41591-025-03743-2?ref=runtimewire as support for advancing the program. Why it matters for AI drug discovery The practical question now is whether an AI-originated target-and-molecule story can translate into clinically meaningful efficacy and safety in a large, late-stage population. The field has spent years raising capital and signing partnerships on that premise. A Phase III readout will put less weight on platform claims and more on patient outcomes. Status Rentosertib remains investigational and has not been approved by regulators. Insilico continues to frame the program as an example of applying AI across discovery and development; Phase III is where that narrative meets the clinical bar that determines whether a drug helps patients with IPF.